Bevacizumab‐induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|9|1456-1462

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.9, 2015-05, pp. : 1456-1462

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab

By  

CANCER, Vol. 119, Iss. 19, 2013-10 ,pp. : 3479-3488

John Wiley & Sons Inc

Access to resources Recommend Favorite

Favorable Clinical Course of Patients Experiencing Bevacizumab-Induced Proteinuria

By  

Case Reports in Oncology, Vol. 3, Iss. 3, 2010-10 ,pp. : 368-371

Karger

Access to resources Recommend Favorite

Bevacizumab and irinotecan for glioblastoma

By  

PEDIATRICS INTERNATIONAL, Vol. 57, Iss. 1, 2015-02 ,pp. : 169-171

John Wiley & Sons Inc

Access to resources Recommend Favorite

Managing Patients Treated with Bevacizumab Combination Therapy

By  

Oncology, Vol. 69, Iss. 3, 2005-11 ,pp. : 25-33

Karger

Access to resources Recommend Favorite

Single-Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Pathway and Outcomes of Patients Treated with First-Line Cytotoxic Chemotherapy Combined with Bevacizumab for Advanced Colorectal Cancer

By  

Oncology, Vol. 87, Iss. 5, 2014-08 ,pp. : 280-292

Karger

Access to resources Recommend Favorite